ANI Pharmaceuticals (ANIP) Price & Analysis

Q: What was ANI Pharmaceuticals Inc’s price range in the past 12 months?

ANI Pharmaceuticals Inc lowest stock price was $52.50 and its highest was $99.50 in the past 12 months.

Q: What is ANI Pharmaceuticals Inc’s market cap?

ANI Pharmaceuticals Inc’s market cap is $1.95B.

Q: When is ANI Pharmaceuticals Inc’s upcoming earnings report date?

ANI Pharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2025 which is in 21 days.

Q: How were ANI Pharmaceuticals Inc’s earnings last quarter?

ANI Pharmaceuticals Inc released its earnings results on Aug 08, 2025. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.406 by $0.394.

Q: Is ANI Pharmaceuticals Inc overvalued?

According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does ANI Pharmaceuticals Inc pay dividends?

ANI Pharmaceuticals Inc does not currently pay dividends.

Q: What is ANI Pharmaceuticals Inc’s EPS estimate?

ANI Pharmaceuticals Inc’s EPS estimate is 1.73.

Q: How many shares outstanding does ANI Pharmaceuticals Inc have?

ANI Pharmaceuticals Inc has 21,688,772 shares outstanding.

Q: What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?

ANI Pharmaceuticals Inc reported an EPS of $1.8 in its last earnings report, beating expectations of $1.406. Following the earnings report the stock price went up 18.07%.

Q: Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ANIP

Compare

322 Followers

ANIP Stock Chart & Stats

$88.61

<$0.01(0.02%)

At close: Jan 08 4:00 PM EST

$88.61

<$0.01(0.02%)

Day’s Range― - ―

52-Week Range$52.50 - $99.50

Previous CloseN/A

Volume18.69K

Average Volume (3M)347.14K

Market Cap

$1.95B

Enterprise Value$1.75B

Total Cash (Recent Filing)$217.80M

Total Debt (Recent Filing)$320.08M

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Nov 05, 2025

EPS Estimate

1.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.80

Shares Outstanding21,688,772

10 Day Avg. Volume304,946

30 Day Avg. Volume347,145

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.90

Enterprise Value/Revenue2.34

Enterprise Value/Gross Profit4.04

Enterprise Value/Ebitda18.51

Forecast

1Y Price Target

$104.43

Price Target Upside17.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Growth PotentialCortrophin Gel is seen as a highly-durable growth driver for the company, with plenty of room in the market for additional uptake.

Market PositionCortrophin Gel is the only ACTH therapy with an indication for acute gout flares, positioning it uniquely in the market.

Bears Say

Revenue ConcernsInvestors wonder if the $97-103M guide for Iluvien is optimistic given 1H25 revenues of $38M and weakness in the ophthalmology buy-and-bill market.

ANI Pharmaceuticals News

ANI Pharmaceuticals price target raised to $90 from $77 at Truist

Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $90 from $77 and keeps a Hold...

6d ago

ANIP

ANI Pharmaceuticals price target raised to $115 from $95 at JPMorgan

JPMorgan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $115 from $95 and keeps an Overweight...

21d ago

ANIP

ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $121 from $93...

28d ago

ANIP

ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares

The latest announcement is out from ANI Pharmaceuticals ( ($ANIP) ). On November 19, 2021, ANI Pharmaceuticals completed...

18d ago

ANIP

Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion

Analyst Ekaterina Knyazkova from J.P. Morgan maintained a Buy rating on ANI Pharmaceuticals and increased the price target...

21d ago

ANIP

ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $114 from $86 and...

1M ago

ANIP

ANI Pharmaceuticals Highlights Commercialization Focus Amid Challenges

The latest announcement is out from ANI Pharmaceuticals ( ($ANIP) ). ANI Pharmaceuticals‘ recent investor presentation highlights the...

1M ago

ANIP

ANI Pharmaceuticals’ Record Earnings and Optimistic Outlook

Ani Pharmaceuticals (($ANIP)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

ANIP

ANI Pharmaceuticals price target raised to $77 from $65 at Truist

Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $77 from $65 but keeps a Hold...

2M ago

ANIP

ANI Pharmaceuticals Reports Record Growth in Q2 2025

Ani Pharmaceuticals ( ($ANIP) ) has released its Q2 earnings. Here is a breakdown of the information Ani...

2M ago

ANIP

ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $93 from $84 and keeps a...

2M ago

ANIP

ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler

Piper Sandler analyst David Amsellem raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $94 from $80...

2M ago

ANIP

Morning Movers: Under Armour sinks following second quarter earnings

Stock futures are edging higher amid growing expectations that the Federal Reserve may move toward dovish policies, spurred...

2M ago

AMR

ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42

Reports Q2 revenue $211.4M, consensus $190.11M. “We had another record-setting quarter for our Company, with all-time highs in...

2M ago

ANIP

ANIP FAQ

What was ANI Pharmaceuticals Inc’s price range in the past 12 months?

ANI Pharmaceuticals Inc lowest stock price was $52.50 and its highest was $99.50 in the past 12 months.

What is ANI Pharmaceuticals Inc’s market cap?

ANI Pharmaceuticals Inc’s market cap is $1.95B.

When is ANI Pharmaceuticals Inc’s upcoming earnings report date?

ANI Pharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2025 which is in 21 days.

How were ANI Pharmaceuticals Inc’s earnings last quarter?

ANI Pharmaceuticals Inc released its earnings results on Aug 08, 2025. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.406 by $0.394.

Is ANI Pharmaceuticals Inc overvalued?

According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ANI Pharmaceuticals Inc pay dividends?

ANI Pharmaceuticals Inc does not currently pay dividends.

What is ANI Pharmaceuticals Inc’s EPS estimate?

ANI Pharmaceuticals Inc’s EPS estimate is 1.73.

How many shares outstanding does ANI Pharmaceuticals Inc have?

ANI Pharmaceuticals Inc has 21,688,772 shares outstanding.

What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?

ANI Pharmaceuticals Inc reported an EPS of $1.8 in its last earnings report, beating expectations of $1.406. Following the earnings report the stock price went up 18.07%.

Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ANIP

ANI Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-2.82%

Trailing 12-Months

Asset Growth

45.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals (ANIP) Earnings & Revenues

Historic Earnings Reports

ANIP Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue growth and successful product performances, particularly for Cortrophin Gel, along with raised financial guidance. However, it also acknowledged market access challenges in the retina segment and an ongoing legal dispute.View all ANIP earnings summaries

ANIP Stock 12 Month Forecast

Average Price Target

$104.43

▲(17.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"54":"$54","71":"$71","88":"$88","105":"$105","122":"$122"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[54,71,88,105,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.18,92.55076923076923,94.92153846153846,97.2923076923077,99.66307692307693,102.03384615384616,104.40461538461538,106.77538461538461,109.14615384615385,111.51692307692308,113.8876923076923,116.25846153846155,118.62923076923076,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.18,91.27615384615385,92.3723076923077,93.46846153846154,94.5646153846154,95.66076923076923,96.75692307692309,97.85307692307693,98.94923076923078,100.04538461538462,101.14153846153847,102.23769230769231,103.33384615384617,{"y":104.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.18,90.16615384615385,90.1523076923077,90.13846153846154,90.1246153846154,90.11076923076924,90.09692307692308,90.08307692307693,90.06923076923077,90.05538461538461,90.04153846153847,90.0276923076923,90.01384615384616,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >